Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2017, Vol. 44 Issue (2): 226-229    DOI: 10.12891/ceog3474.2017
Original Research Previous articles | Next articles
Assessment of 8-hydroxydeoxyguanosine levels in patients with preeclampsia: a prospective study
S. Akinci1, H. Ç. Özcan1, *(), Ö. Balat1, M.G. Uğur1, E. Öztürk2, S. Taysi3, S. Sucu4
1 Gaziantep University, School of Medicine, Dpt. of Obstetrics and Gynecology, Gaziantep, Turkey
2 Medipol University, School of Medicine, Dpt. of Obstetrics and Gynecology, Istanbul, Turkey
3 Gaziantep University, School of Medicine, Dpt. of Biochemistry, Gaziantep, Turkey
4 Gaziantep Cengiz Gokcek Maternity Hospital, Dpt. of Obstetrics and Gynecology/Gaziantep, Turkey
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of investigation: To determine the levels of 8-hydroxydeoxyguanosine (8-OHdG) in preeclampsia (PE) using (enzymelinked immunosorbent assay (ELISA) method. Materials and Methods: Twenty-two pregnant women with severe PE, 18 pregnant women with mild PE, and 40 healthy pregnant women, all between 25 and 41 weeks of gestation, were enrolled in this prospective controlled study. 8-OHdG levels in maternal serum were measured using ELISA method. Results: The authors observed no statistically significant difference in 8-OHdG levels between the mild-severe PE and control groups (p = 0.208). Conclusion: The present results do not support the concept that 8-OHdG has a role in the etiopathogenesis of PE.
Key words:  Oxidative stress      Preeclampsia      8-hydroxydeoxyguanosine     
Published:  10 April 2017     
*Corresponding Author(s):  H. CAGLAYAN OZCAN     E-mail:  ozcan.caglayan8@hotmail.com

Cite this article: 

S. Akinci, H.Ç. Özcan, Ö. Balat, M.G. Uğur, E. Öztürk, S. Taysi, S. Sucu. Assessment of 8-hydroxydeoxyguanosine levels in patients with preeclampsia: a prospective study. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 226-229.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3474.2017     OR     https://ceog.imrpress.com/EN/Y2017/V44/I2/226

[1] H.M. Kim, Y.S. Choo, W.J. Seong. Serum NT-proBNP levels as a marker for cardiopulmonary function in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 511-515.
[2] H. Yolli, M.E. Demir, R. Yildizhan. Neutrophil gelatinase associated lipocalin-2 (Ngal) levels in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 519-523.
[3] A.E. Kholeif, M.Y. Khamis, S. Eltabakh, R.S. Swilam, A. Elhabashy, R. EISherif. Prediction of severity of preeclampsia in Egyptian patients: role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and C-reactive protein[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 183-188.
[4] J. W. Kim, Y. H. Kim, J. H. Moon, H. A. Jung, E. J. Noh. The efficacy of third-generation cephalosporin plus metronidazole versus third-generation cephalosporin plus clarithromycin in neonatal outcomes and oxidative stress markers in women with preterm premature rupture of membranes[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 194-198.
[5] J. Yoon Park, S.W. Lee, K.J. Oh, J.-S. Hong. High mean blood pressure during the first trimester is predictive of future preeclampsia development in healthy pregnant women: a cohort study in Korea[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 770-775.
[6] Y.E. Purut, E.E. Buyukbayrak, F. Ercan, A. Orcun, M. Menke, A.Y. Karageyim Karsidag. Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 195-200.
[7] E. Ertekin, Ö. Tunçyürek, S. Kafkas, Y. Özsunar. Does the placental strain ratio correlate with the umbilical artery Doppler values?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 227-230.
[8] S. Yaman, N. Hançerlioğulları, A. Tokmak, S. Ayhan, M. Alış ık, Ö. Erel. Impaired serum thiol/disulphide homeostasis may be another explanation for the pathogenesis of missed abortion[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 50-54.
[9] A. Simsek, S. Uludag, A. Tuten, A. S. Acikgoz, S. Uludag. Maternal and perinatal outcomes in early onset and late onset preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 837-841.
[10] B. Dullaert, S. Schroven, Y. Jacquemyn. The effect of maternal vitamin D status on pregnancy outcome and child health in the first year of life[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 677-681.
[11] Jinqi Ma, Hua Yao. Persistent hypertension post-preeclampsia: a tertiary care centre-based study in China[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 741-744.
[12] R. Einikytė, A. Dapkeviciute, V. Dzenkeviciute, S. Kasnauskiene, V. Sapoka, D. Ramasauskaite. The importance of angiogenic and antiangiogenic biomarkers in pathogenesis and early diagnosis of preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 485-492.
[13] H. Kobayashi, T. Tsunemi, J. Akasaka, N. Koike, A. Shigemitsu. F. Ito, Y. Yamada, E. Fujii. Preeclampsia as a parental epigenetic disease[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 493-502.
[14] A. Jafari, S. Parchami, S. Reiisi, S. Miraj. Association of plasma homocysteine, folic acid levels, and C677T polymorphism in methylene tetra hydrofolate reductase with risk of preeclampsia: a case-control study in Iranian women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 367-374.
[15] E. Shim, J.Y. Park, H.J. Seol. Placental expression of retinol-binding protein 4 in patients with preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 98-101.
No Suggested Reading articles found!